WO2005004874A1 - Preparation medicinale lyophilisee stable contenant de la tetrodotoxine - Google Patents
Preparation medicinale lyophilisee stable contenant de la tetrodotoxine Download PDFInfo
- Publication number
- WO2005004874A1 WO2005004874A1 PCT/CN2004/000736 CN2004000736W WO2005004874A1 WO 2005004874 A1 WO2005004874 A1 WO 2005004874A1 CN 2004000736 W CN2004000736 W CN 2004000736W WO 2005004874 A1 WO2005004874 A1 WO 2005004874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrodotoxin
- preparation
- content
- preparation according
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA06000243A MXPA06000243A (es) | 2003-07-14 | 2004-07-02 | Formulacion farmaceutica liofilizada estable de tetrodotoxina. |
CA2529598A CA2529598C (en) | 2003-07-14 | 2004-07-02 | Stable freeze-dried pharmaceutical formulation of tetrodotoxin |
JP2006519747A JP2007507422A (ja) | 2003-07-14 | 2004-07-02 | テトロドトキシンの安定な凍結乾燥医薬製剤 |
EP04738334A EP1645277A4 (en) | 2003-07-14 | 2004-07-02 | STABLE FREEZE DRYING MEDICAL TETRODOTOXINE PREPARATION |
CNB200480016097XA CN100457110C (zh) | 2003-07-14 | 2004-07-02 | 稳定的医药用河豚毒素冷冻干燥制剂 |
BRPI0412002-7A BRPI0412002A (pt) | 2003-07-14 | 2004-07-02 | formulação farmacêutica liofilizada estável de tetrodotoxina |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031460208A CN1568999A (zh) | 2003-07-14 | 2003-07-14 | 稳定的医药用河豚毒素冷冻干燥制剂 |
CN03146020.8 | 2003-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005004874A1 true WO2005004874A1 (fr) | 2005-01-20 |
Family
ID=33752652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000736 WO2005004874A1 (fr) | 2003-07-14 | 2004-07-02 | Preparation medicinale lyophilisee stable contenant de la tetrodotoxine |
Country Status (10)
Country | Link |
---|---|
US (3) | US8124608B2 (zh) |
EP (1) | EP1645277A4 (zh) |
JP (1) | JP2007507422A (zh) |
KR (1) | KR20060096411A (zh) |
CN (2) | CN1568999A (zh) |
BR (1) | BRPI0412002A (zh) |
CA (1) | CA2529598C (zh) |
MX (1) | MXPA06000243A (zh) |
WO (1) | WO2005004874A1 (zh) |
ZA (1) | ZA200510106B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031346A1 (zh) * | 2008-09-17 | 2010-03-25 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
US8975242B2 (en) | 2005-03-14 | 2015-03-10 | Wyeth Llc | Tigecycline compositions and methods of preparation |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568999A (zh) * | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
CN101039675A (zh) * | 2004-09-22 | 2007-09-19 | 埃斯蒂文博士实验室股份有限公司 | 河豚毒素及其衍生物用于治疗外周神经源性神经痛 |
WO2007025213A2 (en) * | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Use of sodium channel blockers for the management of musculoskeletal pain |
EP1928452A4 (en) * | 2005-08-25 | 2010-09-01 | Wex Medical Ltd | USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
CN103271920A (zh) * | 2006-03-27 | 2013-09-04 | 威克斯医药有限公司 | 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途 |
CN101239061B (zh) * | 2006-10-18 | 2011-05-11 | 江苏宏锦天药业有限公司 | 氨基全氢化喹唑啉类化合物清除生物体内瘦肉精的用途 |
WO2008088174A1 (en) * | 2007-01-19 | 2008-07-24 | Sang Gil Lee | The composition comprising swellfish extracts using protease, and a manufacturing method thereof |
CN101450056B (zh) * | 2007-12-06 | 2013-04-24 | 江苏宏锦天药业有限公司 | 钠离子通道阻断剂用于治疗抗生素对生物耐药性的新用途 |
CN101554368B (zh) * | 2008-04-07 | 2013-06-12 | 江苏宏锦天药业有限公司 | 一种室温稳定的注射用替曲朵辛组合物制剂 |
CN102020653A (zh) * | 2009-09-22 | 2011-04-20 | 江苏宏锦天药业有限公司 | 氨基全氢化喹唑啉类化合物及其衍生物制备提高抗癌药药效的新应用 |
IN2013MU01127A (zh) | 2013-03-26 | 2015-05-01 | Astron Res Ltd | |
KR101398764B1 (ko) | 2013-08-29 | 2014-05-27 | 강릉원주대학교산학협력단 | 입자의 이동에 의해 분석물질을 검출하는 장치 및 방법 |
CN111122752B (zh) * | 2020-02-26 | 2022-06-10 | 浙江清华长三角研究院 | 一种河豚毒素成分分析标准物质的制备方法 |
CN112704665A (zh) * | 2021-01-08 | 2021-04-27 | 江苏宏锦天药业有限公司 | 替曲朵辛口服制剂、替曲朵辛冻干片及其应用 |
CN115475151A (zh) * | 2022-08-14 | 2022-12-16 | 中国人民解放军海军军医大学 | 河豚毒素缓释微球及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995024903A1 (fr) * | 1994-03-17 | 1995-09-21 | Nanning Maple Leaf Pharmaceutical Co., Ltd. | Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes |
CN1145225A (zh) * | 1996-09-24 | 1997-03-19 | 王维国 | 用于戒毒、镇痛的药剂及其制法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2912361A (en) * | 1956-11-28 | 1959-11-10 | Sterling Drug Inc | Canine distemper vaccine and its preparation |
JPS5967228A (ja) * | 1982-10-07 | 1984-04-16 | Green Cross Corp:The | 寒冷不溶性グロブリンの凍結乾燥方法 |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
EP0857484A4 (en) * | 1995-09-13 | 2000-12-06 | Nippon Shinyaku Co Ltd | PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF |
JP2937135B2 (ja) * | 1995-09-13 | 1999-08-23 | 日本新薬株式会社 | Pge1含有凍結乾燥製剤及び製法 |
US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
US6326020B1 (en) | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
EP1058547B1 (en) * | 1998-03-03 | 2005-11-23 | Shionogi & Co., Ltd. | Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
CN1203857C (zh) * | 2000-09-18 | 2005-06-01 | 威克斯医药有限公司 | 局部麻醉与镇痛的新方法 |
CN1240702C (zh) * | 2000-09-18 | 2006-02-08 | 威克斯医药有限公司 | 高获得率提取替曲朵辛的方法 |
CN1284536C (zh) * | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
CN1187356C (zh) * | 2000-11-22 | 2005-02-02 | 南宁枫叶药业有限公司 | 高获得率提取替曲朵辛的系统 |
CN1187355C (zh) * | 2000-11-22 | 2005-02-02 | 南宁枫叶药业有限公司 | 精制高纯度替曲朵辛的方法 |
CN1236773C (zh) * | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
CN1203860C (zh) * | 2001-06-22 | 2005-06-01 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
CN100360133C (zh) | 2002-05-23 | 2008-01-09 | 潘心富 | 用于戒毒、镇痛的河豚毒素呼吸道给药制剂 |
CN1158285C (zh) * | 2002-06-24 | 2004-07-21 | 厦门一元生物工程有限公司 | 河豚毒素高纯单体规模化制备方法 |
CN1568999A (zh) * | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
US20090143415A1 (en) | 2004-09-21 | 2009-06-04 | Wex Pharmaceuticals, Inc. | Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain |
CN101039675A (zh) | 2004-09-22 | 2007-09-19 | 埃斯蒂文博士实验室股份有限公司 | 河豚毒素及其衍生物用于治疗外周神经源性神经痛 |
EP1928452A4 (en) | 2005-08-25 | 2010-09-01 | Wex Medical Ltd | USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT |
CN103271920A (zh) | 2006-03-27 | 2013-09-04 | 威克斯医药有限公司 | 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途 |
-
2003
- 2003-07-14 CN CNA031460208A patent/CN1568999A/zh active Pending
-
2004
- 2004-07-02 CA CA2529598A patent/CA2529598C/en active Active
- 2004-07-02 CN CNB200480016097XA patent/CN100457110C/zh active Active
- 2004-07-02 KR KR1020067000851A patent/KR20060096411A/ko not_active Application Discontinuation
- 2004-07-02 JP JP2006519747A patent/JP2007507422A/ja active Pending
- 2004-07-02 BR BRPI0412002-7A patent/BRPI0412002A/pt not_active IP Right Cessation
- 2004-07-02 EP EP04738334A patent/EP1645277A4/en active Pending
- 2004-07-02 MX MXPA06000243A patent/MXPA06000243A/es unknown
- 2004-07-02 WO PCT/CN2004/000736 patent/WO2005004874A1/zh active Application Filing
- 2004-07-14 US US10/890,279 patent/US8124608B2/en active Active
-
2005
- 2005-12-12 ZA ZA200510106A patent/ZA200510106B/xx unknown
-
2009
- 2009-12-31 US US12/650,864 patent/US8222258B2/en active Active
-
2012
- 2012-06-26 US US13/533,907 patent/US8530481B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995024903A1 (fr) * | 1994-03-17 | 1995-09-21 | Nanning Maple Leaf Pharmaceutical Co., Ltd. | Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes |
CN1145225A (zh) * | 1996-09-24 | 1997-03-19 | 王维国 | 用于戒毒、镇痛的药剂及其制法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1645277A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8975242B2 (en) | 2005-03-14 | 2015-03-10 | Wyeth Llc | Tigecycline compositions and methods of preparation |
US9254328B2 (en) | 2005-03-14 | 2016-02-09 | Wyeth Llc | Tigecycline compositions and methods of preparation |
US9694078B2 (en) | 2005-03-14 | 2017-07-04 | Wyeth Llc | Tigecycline compositions and methods of preparation |
US10588975B2 (en) | 2005-03-14 | 2020-03-17 | Wyeth Llc | Tigecycline compositions and methods of preparation |
EP1858488B2 (en) † | 2005-03-14 | 2022-07-20 | Wyeth LLC | Tigecycline compositions and methods of preparation |
WO2010031346A1 (zh) * | 2008-09-17 | 2010-03-25 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
ZA200510106B (en) | 2009-09-30 |
KR20060096411A (ko) | 2006-09-11 |
CN1835754A (zh) | 2006-09-20 |
US20050020610A1 (en) | 2005-01-27 |
JP2007507422A (ja) | 2007-03-29 |
CN100457110C (zh) | 2009-02-04 |
US20100249150A1 (en) | 2010-09-30 |
US8530481B2 (en) | 2013-09-10 |
US8124608B2 (en) | 2012-02-28 |
BRPI0412002A (pt) | 2006-08-15 |
CA2529598C (en) | 2017-03-07 |
CA2529598A1 (en) | 2005-01-20 |
CN1568999A (zh) | 2005-01-26 |
US20120264767A1 (en) | 2012-10-18 |
MXPA06000243A (es) | 2006-04-07 |
EP1645277A4 (en) | 2011-08-17 |
US8222258B2 (en) | 2012-07-17 |
EP1645277A1 (en) | 2006-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005004874A1 (fr) | Preparation medicinale lyophilisee stable contenant de la tetrodotoxine | |
JPH0413325B2 (zh) | ||
US20190105392A1 (en) | Caspofungin Acetate Formulations | |
MX2011004991A (es) | Complejos de inclusion de pinocembrina con ciclodextrina o sus derivados. | |
EP3650009A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
WO2008086698A1 (fr) | Forme injectable de forsythoside et préparation de celle-ci | |
EP2620153B1 (en) | 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor | |
JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
WO2007124668A1 (fr) | Composition pharmaceutique comportant un concentré élevé de polydatine | |
WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
CN106943346B (zh) | 甲地高辛液体制剂、其制备方法及其用途 | |
WO2010031346A1 (zh) | 河豚毒素冻干粉针制剂及其制备方法 | |
JPS63253022A (ja) | バクロフエン外用製剤 | |
CN110139641B (zh) | 外用组合物 | |
CN104800172B (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN111789818B (zh) | 注射用盐酸罂粟碱药物组合物及制备方法 | |
TW201440783A (zh) | 含有米卡芬淨或其鹽的醫藥組成物 | |
JP2001163776A (ja) | 安定化された液剤 | |
CN103271880A (zh) | 一种头孢地嗪钠注射剂及其制备方法 | |
CN108289897B (zh) | 一种瑞马唑仑的药物组合物 | |
WO2009103209A1 (zh) | 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 | |
EP3834825A1 (en) | Busulfan composition, preparation method therefor and application thereof | |
WO2019069316A1 (en) | STABLE COMPOSITION OF BEGINSTAT, METHODS FOR PRODUCTION THEREOF AND USES THEREOF | |
US20140275122A1 (en) | Voriconazole Formulations | |
WO2014007239A1 (ja) | アムホテリシンb含有組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004816097X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200510106 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5833/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2529598 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004738334 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/000243 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000851 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006519747 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004738334 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0412002 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067000851 Country of ref document: KR |